0455.HK HKSE
Tianda Pharmaceuticals Limited
1W: -8.5%
1M: +6.3%
3M: +38.8%
YTD: +14.6%
1Y: -34.1%
3Y: -50.3%
5Y: -41.9%
HK$0.12 ($0.02)
-0.00 (-1.67%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Cash Flow Trends
Operating Cash Flow
-$10M
+80.5% ▲
Capital Expenditures
$43M
+35.7% ▲
5Y CAGR: -16.1%
Free Cash Flow
-$52M
+54.9% ▲
Dividends Paid
$6M
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$77M
+56.8% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$27M | -$28M | -$55M | -$24M | -$54M |
| Depreciation & Amort. | $21M | $22M | $50M | $36M | $38M |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$23M | $19M | $85M | -$58M | $15M |
| Other Non-Cash Items | -$8M | -$22M | $121M | -$4M | -$8M |
| Operating Cash Flow | -$38M | -$8M | $79M | -$50M | -$10M |
| — Investing Activities — | |||||
| Capital Expenditures | -$146M | -$54M | -$24M | -$49M | -$26M |
| Acquisitions (Net) | $766K | $152M | $1M | $0 | $0 |
| Investment Purchases | -$264M | -$327M | -$102M | -$306M | -$92M |
| Investment Sales | $269M | $313M | $113M | $300M | $102M |
| Other Investing | $2M | $2M | $20M | -$14M | -$16M |
| Investing Cash Flow | -$138M | $86M | -$12M | -$69M | -$32M |
| — Financing Activities — | |||||
| Net Debt Issuance | $105M | $13M | $0 | -$21M | -$19M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$3M | -$9M | -$18M | -$6M | -$6M |
| Other Financing | -$12M | -$5M | -$11M | -$31M | -$6M |
| Financing Cash Flow | $91M | -$1M | -$29M | -$57M | -$31M |
| Net Change in Cash | -$64M | $86M | $105M | -$178M | -$77M |
| Cash End of Period | $248M | $334M | $340M | $162M | $86M |
| Free Cash Flow | -$184M | -$62M | $55M | -$116M | -$52M |